Table 3.
Characteristic | All targets (n = 160) | Framed cases (n = 80) | Frameless cases (n = 80) |
---|---|---|---|
Prescription dose | 21 Gy (14-24) | 20.5 Gy (14-24) | 21 Gy (18-24) |
Isodose line | 53% (50-94) | 54% (50-94) | 50% (50-90) |
Target volume | 0.077 mL (0.002-6.15) | 0.089 mL (0.002-6.15) | 0.069 mL (0.003-4.39) |
Age | 58 (30-91) | 58 (30-84) | 60 (44-91) |
Sex | |||
Male | 56 (35%) | 30 (38%) | 26 (33%) |
Female | 104 (65%) | 50 (62%) | 54 (67%) |
Primary | |||
Lung | 76 (48%) | 36 (45%) | 40 (50%) |
Breast | 61 (38%) | 33 (41%) | 28 (35%) |
Melanoma | 17 (10%) | 8 (10%) | 9 (11%) |
GI | 3 (2%) | 1 (2%) | 2 (2%) |
Other* | 3 (2%) | 2 (2%) | 1 (2%) |
Renal cell carcinoma, urothelial carcinoma, and thyroid cancer.
Abbreviation: GI = gastrointestinal.